Amgen Inc. Proceeds from Divestiture of Businesses
Amgen Inc. (AMGN) had Proceeds from Divestiture of Businesses of $130.00 million as of 2022-11-02, per its 10-K filed 2025-02-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2025-02-14
- 2022-11-02: Proceeds from Divestiture of Businesses $130.00M.
| Period end | Proceeds from Divestiture of Businesses |
|---|---|
| 2022-11-02 | $130.00M 10-K · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |